Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine vs Risperidone for Negative Symptoms in Schizophrenia
NCT00305422Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of quetiapine in schizophrenia (2 arms), sponsored by AstraZeneca. Primary endpoint: Clinical efficacy of both neuroleptics, especially with regard to cognitive deficits and functional brain activation at 12 weeks. Started Nov 2001; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00305422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305422.